2 fast growth ASX shares that could be buys in December 2021

Volpara is one of the ASX growth shares that could be compelling in December 2021.

| More on:
Mother and young children at doctors

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX growth shares increasing in size quickly could be contenders for an investor's portfolio.

There is growing volatility in the ASX share market. This may open up some better value opportunities for people to find.

Share prices regularly change, but lower prices give the chance getting exposure to quality companies at the best prices.

Here are two of them:

Doctor Care Anywhere Group PLC (ASX: DOC)

Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its platform. It has relationships with health insurers, healthcare providers and corporate customers to connect with a range of telehealth services.

It also recently completed the acquisition of Australian telehealth and tele-mental provider GP2U Telehealth. This gives the business another avenue for growth and geographical diversification. The ASX growth share has also entered the self-pay market in the Republic of Ireland through its channel partner Boots.

It's expecting to report 2021 revenue growth of at least 100% compared to FY20, excluding the acquisition.

The three months to 30 September 2021 saw growth with a number of metrics. Quarter on quarter revenue growth was 21.6% to AU$10.7 million. Consultations grew by 30.6% to 116,800 with over 65% of consultations delivered to returning patients.

Activated lives reached 603,200 during the quarter – up 8% quarter on quarter. An activated life is the total number of people who have signed up for Doctor Care Anywhere's service and entered their personal details.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara describes itself as a health technology software company with an integrated platform which assists in the delivery of personalised breast care.

The ASX growth share grew its subscription revenue by 35% to NZ$11.8 million in the first half of FY22. Its revenue comes with a very high gross profit margin of 91.4%.

Its market share of women who have at least one Volpara product used on their image is around 34%.

Volpara says that its strategic commercial partnerships will help it achieve greater reach in not only genetic testing for breast cancer but expansion into the US lung cancer market where AI and software offer the prospect of saving many more lives.

It has partnered with a number of different organisations, including in lung, with RevealDx, Riverain Technologies, Natera and Invitae.

The company has a number of areas of focus for growth such as expanding the electronic health record (EHR) sales channel. It's also working on building its data platform in a key effort to change from screening for detection to prevention.

It's expecting to reach revenue of between NZ$25 million to NZ$26 million in this financial year.

Volpara management said the next few months is going to be "incredibly busy and exciting" as it heads to Chicago for the large radiology conference RSNA. The third and fourth quarters of the year are traditionally the biggest quarters for the business.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Doctor Care Anywhere Group PLC and VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

a business person in a suit and tie directs a pointed finger upwards with a graphic of a rising bar graph and an arrow heading upwards in line with the person's finger.
Growth Shares

These ASX 200 growth shares could be strong buys in March

Goldman Sachs is feeling bullish about these growth stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Growth Shares

1 ASX growth stock down 30% to buy right now

The market has reacted badly to this ASX 200 company's half-year result. This could be your chance to get in.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Growth Shares

This ASX growth stock is down 25%: Buy, sell, or hold?

Analysts have given their verdict on this beaten down growth share.

Read more »

A woman shows her phone screen and points up.
Growth Shares

2 ASX shares showing 'strong growth' that offer value right now

This pair of quality stocks have upward momentum that can't be denied right now, rising 38% and 15% since the…

Read more »

A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach
Growth Shares

I'd buy these great ASX growth shares in March

Growth stocks could achieve strong returns.

Read more »

A woman smiles as she sits on the bus using her phone and listening to music through headphones.
Growth Shares

1 ASX stock I think is just as hot as Nvidia (without all the hype)

There is an Australian business going as well as the US chip maker. Check this out.

Read more »

Happy man working on his laptop.
Growth Shares

1 ASX growth stock down 40% to buy right now

Goldman Sachs thinks this beaten down stock could be great value.

Read more »

A woman holds a tape measure against a wall painted with the word BIG, indicating a surge in gowth shares
Growth Shares

Goldman Sachs says these ASX growth shares are destined for big things

There's a reason Goldman has slapped buy ratings on these shares.

Read more »